|Bid||117.02 x 1200|
|Ask||118.91 x 900|
|Day's range||115.26 - 118.76|
|52-week range||72.13 - 120.53|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||52.35|
|Forward dividend & yield||2.32 (1.96%)|
|Ex-dividend date||21 Dec 2020|
|1y target est||N/A|
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arnoldas Giedrimas, M.D., also at Southcoast Health. The PULSED AF Trial is the first global, pre-market, multi-center clinical study with IDE approval aimed to establish the safety and efficacy of the PulseSelect System.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new analysis of the REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) clinical trial shows that patients whose heart failure stabilizes with CRT live longer, similar to patients whose condition improves with CRT. The manuscript was recently published in the Journal of American College of Cardiology: Clinical Electrophysiology.
Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2021, which ended January 29, 2021.